Pentostatin

Generic Name: Pentostatin

Brand Names: Nipent

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₆N_₄O_₄

CAS Number: 53910-25-1

Unique Ingredient Identifier: 395575MZO7

Background: A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Indication: For the treatment of hairy cell leukaemia refractory to alpha interferon.

Associated Conditions: Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease

Associated Therapies: -

Clinical Trials

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Phase 1

Recruiting

Conditions: Recurrent Severe Aplastic Anemia
Refractory Severe Aplastic Anemia

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Procedure: Haploidentical Hematopoietic Cell Transplantation
Drug: Pentostatin
Other: Questionnaire Administration

First Posted Date: 2023-03-07

Last Posted Date: 2024-12-31

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 6

Registration Number: NCT05757310

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Blood Stem Cell Transplant for Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease
Hemoglobinopathies
Thalassemia
Anemia, Sickle Cell
Sickle Cell Disorder

Interventions: Drug: Cyclophosphamide
Drug: Pentostatin
Drug: Rabbit anti-thymocyte globulin
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

First Posted Date: 2017-08-15

Last Posted Date: 2024-03-07

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT03249831

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3

Completed

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Ruxolitinib
Drug: Extracorporeal photopheresis (ECP)
Drug: Low-dose methotrexate (MTX)
Drug: Mycophenolate mofetil (MMF)
Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
Drug: Infliximab
Drug: Rituximab
Drug: Pentostatin
Drug: Imatinib
Drug: Ibrutinib

First Posted Date: 2017-04-13

Last Posted Date: 2023-07-18

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT03112603

Locations: 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇷🇴
Novartis Investigational Site, Bucharest, Romania

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Procedure: haploidentical stem cell transplant
Drug: Filgrastim
Drug: Sirolimus
Drug: Alemtuzumab
Drug: Pentostatin
Drug: Cyclophosphamide
Drug: Hydroxyurea

First Posted Date: 2017-03-13

Last Posted Date: 2024-08-07

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 57

Registration Number: NCT03077542

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease
Thalassemia
Stem Cell Transplantation
Graft vs Host Disease

Interventions: Drug: Alemtuzumab
Drug: Filgrastim
Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Pentostatin
Procedure: Radiotherapy

First Posted Date: 2014-04-07

Last Posted Date: 2024-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 56

Registration Number: NCT02105766

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Pentostatin
Drug: Cyclophosphamide
Drug: Ofatumumab

First Posted Date: 2012-09-10

Last Posted Date: 2016-12-28

Lead Sponsor: Niguarda Hospital

Target Recruit Count: 47

Registration Number: NCT01681563

Locations: 🇮🇹
IRCCS Policlinico San Matteo Pavia Istituto di Ematologia, Pavia, Italy
🇮🇹
Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia, Brescia, Italy
🇮🇹
Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia, Monza, MB, Italy

and more 9 locations

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Phase 1

Completed

Conditions: Mesothelioma
Pancreatic Neoplasms
Adenocarcinoma of Lung

Interventions: Drug: Pentostatin
Drug: Cyclophosphamide
Biological: SS1(dsFv)PE38 - lot 073I0809
Biological: SS1(dsFv)PE38 - lot FIL129J01

First Posted Date: 2011-05-30

Last Posted Date: 2019-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT01362790

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Pentostatin
Drug: Ofatumumab

First Posted Date: 2011-05-11

Last Posted Date: 2018-05-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01352312

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies

Phase 3

Completed

Conditions: Chronic Myelocytic Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Acute Myelocytic Leukemia
Hodgkin's Disease

Interventions: Drug: Pentostatin
Drug: Methotrexate

First Posted Date: 2010-08-25

Last Posted Date: 2013-03-21

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 6

Registration Number: NCT01188798

Locations: 🇺🇸
St . Jude Children's Research Hospital, Memphis, Tennessee, United States

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2

Active, not recruiting

Conditions: Hairy Cell Leukemia

Interventions: Drug: Rituximab
Drug: Pentostatin
Drug: Bendamustine
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Epinephrine
Drug: Antihistamines
Drug: Corticosteroids
Drug: Bronchodilators
Other: Intravenous (IV) Saline

First Posted Date: 2010-02-01

Last Posted Date: 2024-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT01059786

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy